Private Equity

A new partnership highlights how specialized tech is becoming essential for navigating complex IRA tax rules, de-risking billions in renewable energy projects.

Colombian law firm Contexto Legal appoints Federico Escobar as Managing Partner, signaling a strategic pivot from its founder's legacy to a new era of tech and global growth.

DRI Healthcare's strategic C$109M debt swap lowers interest costs, extends maturity, and signals strong investor confidence to fuel its acquisition pipeline.

Over 200 Wasilla school bus drivers are on strike, disrupting transport for 18,000 students amid a bitter dispute over wages, safety, and alleged unfair labor practices.

With a new unified command under mining veteran Mark Wall, American Rare Earths aims to accelerate its massive Halleck Creek project and secure the U.S. supply chain.

Reinsurance giant RGA hires Jayson Bronchetti, a top CIO known for managing $300B+ portfolios, signaling a new chapter for its investment engine.

Lantheus gains FDA tentative approval for a LUTATHERA rival, signaling new hope for rare cancer patients and a legal battle with Novartis over market access.

WNC CEO Will Cooper, Jr. is the new chairman of BUILD-PAC. Can his deep affordable housing focus reshape federal policy in a critical election year?

After a major turnaround, Genetix Biotherapeutics announces its first profitable quarter and plans to double production of its high-stakes gene therapies.

As Western Canada's housing crisis deepens, Ikigai Impact hires a 'Housing First' expert to lead its expansion and redefine affordable housing investment.

Ramaco Resources' CEO just exercised long-held options, signaling deep confidence as the company navigates a weak coal market and pivots to critical minerals.

Regulatory delays in China scuttled Pulmatrix's merger with Cullgen, forcing the biotech to urgently seek new partners for its promising drug pipeline.

With its sixth deal of 2026, WhiteHawk expands its footprint in the Haynesville Shale, tying its fortunes to the booming but controversial U.S. LNG market.

The infant nutrition giant is entering Canada's booming organic market, betting on brand trust to compete in an increasingly crowded and conscious space.

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

In a deal highlighting intense focus on supply chain resilience, J.F. Lehman acquires critical forgings provider Forged Solutions Group from Arlington Capital.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

Avenacy launches its 26th product, a generic Benadryl injection, tackling drug shortages and aiming to improve patient safety with unique packaging.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.